GlobeNewswire by notified

Elanders AB: Rapport från årsstämman 2022

Dela

Stämman, som leddes av styrelsens ordförande Carl Bennet, beslöt att:

  • fastställa årsredovisningen för 2021,
  • bevilja styrelsens ledamöter och verkställande direktören ansvarsfrihet för verksamhetsåret 2021,
  • enligt styrelsens förslag i kallelsen fastställa att utdelning för 2021 lämnas med 3,60 kronor per aktie samt att avstämningsdagen för utdelning är den 25 april 2022, vilket innebär att utdelningen beräknas utsändas genom Euroclear Sweden AB den 28 april 2022,
  • enligt förslaget i kallelsen för verksamhetsåret 2021 bevilja styrelsen arvode inklusive utskottsarbete om totalt 4 252 000 kronor att fördelas inom styrelsen såsom angivits i kallelsen,
  • enligt förslaget i kallelsen till styrelseledamöter för tiden intill dess att årsstämman 2023 hållits utse:

    Carl Bennet (omval)
    Eva Elmstedt (omval)
    Dan Frohm (omval)
    Erik Gabrielson (omval)
    Cecilia Lager (omval)
    Anne Lenerius (omval)
    Magnus Nilsson (omval)
    Johan Stern (omval)
    Caroline Sundewall (omval)
  • enligt förslaget i kallelsen utse Dan Frohm till styrelsens ordförande,
  • godkänna det i kallelsen lämnade förslaget till omval av revisionsfirman PricewaterhouseCoopers som revisor,
  • valberedningen inför nästa årsstämma ska formeras och fullgöra uppgifter enligt förslaget i kallelsen,
  • godkänna den av styrelsen framlagda ersättningsrapporten avseende ersättningar till ledande befattningshavare, samt
  • godkänna nya riktlinjer för ersättningar till ledande befattningshavare.

I sitt anförande redogjorde koncernchefen Magnus Nilsson för koncernens verksamhet samt utveckling under 2021 och det första kvartalet 2022. Det har varit en period som präglats av covid-19-pandemin, halvledarbrist och en stor osäkerhet i omvärlden. Trots det har Elanders hanterat situationen på ett bra sätt. År 2021 var koncernens resultatmässigt bästa år någonsin. Vidare redogjorde Magnus Nilsson även för de satsningar och förvärv som gjorts. Fashion & Lifestyle blev under året koncernens största kundsegment genom förvärvet av Bergen Logistics i USA.

Protokoll från stämman kommer att finnas tillgängligt på bolagets hemsida så snart det föreligger i justerat skick.

Elanders AB (publ)
Styrelsen

Carl Bennet, styrelsens ordförande, tel: +46 31 741 64 00 eller
Magnus Nilsson, vd och koncernchef, tel: +46 31 750 07 50

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye